Impact of a Cricket and Black Soldier Fly Larvae-Fortified Cracker on the Gut Microbiome and Iron Status in Malagasy Schoolchildren

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age9-13
SponsorCornell University

About this trial

The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.

Specifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Child (male, female, intersex, non-binary), aged 9 to 13 years old who attends one of the selected schools

Caregiver or legal guardian is willing to provide informed consent

Child is willing to provide informed assent

Disqualifiers

Child age is outside the preferred age range (9 to 13 years)

Not enrolled in the participating schools

Unable or unwilling to comply with the study requirements

Illness requiring medical treatment, malaria, severe anemia (hemoglobin (Hb) concentration below 8.0 g/dL as indicated by HemoCue 201+ system), severe acute malnutrition, fever, diarrhea, etc.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Cricket and Black Soldier Fly Larvae-fortified Cracker

    Dietary supplement

    Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.

  • Rice and Corn Cracker

    Dietary supplement

    Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.

Treatment groups

650 Participants
are divided into 2 treatment groups
Group A: TreatmentExperimental treatment 1 intervention
Group B: ControlPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Gut mircrobiome

The investigators will assess gut microbiome composition at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through 16S rRNA sequencing and quantification of fecal biomarkers.

Time frame
From enrollment to the end of treatment after 14 weeks of cracker consumption.
2

Iron via soluble transferrin receptor

The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through soluble transferrin receptor (mg/L).

Time frame
From enrollment to the end of treatment after 14 weeks of cracker consumption.
3

Intestinal inflammation via calprotectin

The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: calprotectin (µg/g).

Time frame
From enrollment to the end of treatment after 14 weeks of cracker consumption.
4

Intestinal inflammation via lactoferrin

The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lactoferrin (µg/g).

Time frame
From enrollment to the end of treatment after 14 weeks of cracker consumption.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cornell University

Lead sponsor

PATH

Collaborator

Institut Pasteur de Madagascar

Collaborator

Université d'Antananarivo

Collaborator

This trial is not recruiting at the moment. You can still explore other options: